Podcasts about Hepatocellular carcinoma

Send us a textIn this Journal of Vascular and Interventional Radiology (JVIR) audio episode, JVIR blog Editor Peter Li, MD, MS, uses artificial intelligence (AI) platform ElevenLabs to produce a podcast discussion on the November 2024 JVIR paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original articleRead the blog entry, "Vox Voxel: Calculating Y90 Tumor Dose and Sphere Distribution with Voxel Dosimetry"SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

This week's episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.

Send us a textThis recording features audio versions of May 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Recurrent Portal Hypertension after Liver Transplant: Impact on Survival and the Role of Transjugular Intrahepatic Portosystemic Shunt Creation in Management ReadNontarget Hemangioma Size Reduction after Bleomycin–Ethiodized Oil Embolization of Primary Hepatic Hemangioma ReadMR–Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma ReadEmbolotherapy for Pulmonary Arteriovenous Malformations in the Pediatric Population with Hereditary Hemorrhagic Telangiectasias—A Retrospective Case Series ReadEffects of Prophylactic Coil Embolization of Pelvic Arteries on Surgical Outcomes in Hemodynamically Stable Patients with Complex Acetabular Fractures ReadPercutaneous Ablation versus Radiotherapy for Pain Related to Bone and Soft Tissue Malignancies: A Multipayor Database Analysis of Outcomes ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Sonya Choe, University of California Riverside School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Ahmed Alzubaidi, Wayne State University School of MedicineIpek Midillioglu, Western University of Health Sciences, College of Osteopathic MedicineNate Wright, Warren Alpert Medical School of Brown University Sanya Dhama, University of California Riverside School of MedicineTiffany Nakla, Touro University Nevada College of Osteopathic MedicineKalei Hering, Harvard Medical School SIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Characteristics and Survival Outcomes of Hepatocellular Carcinoma After the Fontan Operation.

Hepatocellular carcinoma (HCC) disproportionately impacts underserved and minority populations, compounded by systemic barriers in care. These populations face increased risk factors yet often experience delayed diagnoses and limited access to specialists, leading to later-stage detection. In this episode, CANCER BUZZ speaks with Karen S. Waldrop, BSN, RN, OCN, ONN-CG, a GI oncology nurse navigator at UAB O'Neal Comprehensive Cancer, and Henry Rendon, a patient diagnosed with HCC in June 2023. Together, they share insights on the vital role of multidisciplinary teams and how nurse navigators can mitigate access barriers by improving patient outreach, facilitating access to care, and guiding patients through the complexities of the health care system.  “Karen, my nurse navigator, knew everything I was going through. She made sure everything was coordinated and ran smoothly. She communicated clearly and thoroughly every time. I never had to second-guess what was happening. She made sure I was prepared, not just once, but every step of the way.” - Henry Rendon, patient guest with HCC “At our institution, we have a clinic where the patient can see a medical oncologist, a liver medical physician, an interventional radiology specialist, a pharmacist… the whole gamut. If they need social work, we'll pull in social work. If they need palliative care, we'll pull in palliative care. And that's in one visit. For folks with transportation issues or those who live far away, it's truly the best way to get care.” - Karen S. Waldrop, BSN, RN, OCN, ONN-CG   Karen S. Waldrop, BSN, RN, OCN, ONN-CG GI Oncology Nurse Navigator UAB O'Neal Comprehensive Cancer Birmingham, Alabama   Henry Rendon Patient Guest, diagnosed with HCC Helena, Alabama   Additional Resources: Multidisciplinary HCC Care Effective Practices in Care Coordination - https://bit.ly/4lHTpbN HCC Education and Protocols to Advance Treatment through Integrated Collaboration - https://bit.ly/42GpatW Understanding practices and gaps in multidisciplinary hepatocellular carcinoma (HCC) care within the community oncology setting - https://bit.ly/3XT4k84 Building Multidisciplinary Care Capacity for People Impacted by Hepatocellular Carcinoma - https://bit.ly/44rgFUS  

Welcome to this week's podcast by VJOncology, where we delve into the latest developments in adjuvant therapy for hepatocellular carcinoma.... The post Adjuvant Therapy for Hepatocellular Carcinoma appeared first on VJOncology.

This recording features audio versions of April 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Adverse Events After Percutaneous Transhepatic Biliary Drainage: A 10-Year Retrospective Analysis ReadEndovascular Therapy versus Anticoagulation Alone for Subacute Iliofemoral Deep Vein Thrombosis ReadImprovement of Hypoalbuminemia and Hepatic Reserve after Stent Placement for Postsurgical Portal Vein Stenosis ReadSafety and Effectiveness of Yttrium-90 Radioembolization in People Living with Human Immunodeficiency Virus ReadRadiation Segmentectomy and Modified Radiation Lobectomy for Unresectable Early-Stage Intrahepatic Cholangiocarcinoma ReadComparison of Liquid with Particle Embolics in a Translational Rat Model of Hepatocellular Carcinoma: Histologic and Radiographic Responses ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Millennie Chen, University of California Riverside School of MedicineTheodore Addo, Warren Alpert Medical School of Brown UniversityIpek Midillioglu, Western University of Health SciencesDaniel Roh, Loma Linda University School of MedicineSunil Balamurugan, Western University of Health SciencesMark Oliinik, Loma Linda University School of MedicineSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Bertram Bengsch and Dr Henrike Salie from the Department of Internal Medicine II, Medical Centre, University of Freiburg, Freiburg, Germany, on the paper "Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma" published in paper copy in Gut in March 2025.

Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002045. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/37700494/ Fibrosis-4 (FIB-4) Calculator https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 Liver Fibrosis Assessment: MR and US Elastography https://pubmed.ncbi.nlm.nih.gov/34687329/ Using the FIB-4, Automatically Calculated, Followed by the ELF Test in Second Line to Screen Primary Care Patients for Liver Disease https://pubmed.ncbi.nlm.nih.gov/38806580/ American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) https://pubmed.ncbi.nlm.nih.gov/35569886/ Mediterranean Diet and Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/29785077/ Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction https://pubmed.ncbi.nlm.nih.gov/39470028/ Current Status of Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/39801787/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Update on the Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/35110946/

Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.CME information and select publications here.

Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.CME information and select publications here.

Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.CME information and select publications here.

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics: Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry Introduction (0:00) Faculty Presentation (3:08) IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43) Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15) Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34) Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn  Faculty Presentation (31:18) EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15) Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29) Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05) Current First-Line Therapy for Advanced HCC — Dr He Faculty Presentation (1:00:39) Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00) Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22) Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03) Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein  Faculty Presentation (1:29:42) Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59) Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27) Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20) CME information and select publications

Do you know how the experts use immunotherapy to treat their patients with advanced hepatocellular carcinoma (HCC)? Credit available for this activity expires: 2/12/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002179?ecd=bdc_podcast_libsyn_mscpedu

Discover the latest updates from the updated EASL Clinical Practice Guidelines on Hepatocellular Carcinoma (HCC). This episode explores key advancements, their impact on clinical practice, and how they will shape the future of HCC diagnosis, treatment, and management. Join our faculty as they break down the changes and provide practical insights for healthcare professionals.Moderator: Thomas BergFaculty: Peter Galle, Josep Llovet and Lorenza RimassaRelated episodesEASL Studio S6E4: World Cholangiocarcinoma Day: Highlighting Guidelines and Exploring the Horizon BeyondEASL Studio S6E9: Therapy Hierarchy in HCC: A New Kid on the BlockEASL Studio S5E13: Basics in Decision-Making for Liver Cancer TreatmentEASL Studio Live from EASL Congress 2024: Advances in Systemic Treatments in Liver CancerAll EASL Studio Podcasts are available on EASL Campus.

Dr Anthony El-Khoueiry, Dr Richard Finn, Dr Aiwu Ruth He, Dr Stacey Stein and moderator Dr Stephen “Fred” Divers discuss data from the 2025 ASCO GI meeting and other published studies guiding the care of patients with hepatocellular carcinoma.CME information and select publications here.

In the third of this 4-part podcast series on hepatocellular carcinoma (HCC), the Oncology Brothers, Drs. Rahul and Dr Rohit Gosain, are joined by hepatologist Dr. Maria Reig and interventional radiologist Dr. Emil Cohen to explore treatment strategies for patients with intermediate-stage HCC. The experts share valuable insights into the available treatment options for this heterogeneous patient group and explore the role of systemic treatments and multimodal approaches in achieving optimal patient outcomes.   The conversation dives deep into real-world clinical challenges in managing patients with intermediate HCC, including treatment sequencing and strategies based on the experts' experience in clinical practice and the available data. The speakers also highlight variations in practice across different centres and geographic regions. Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Join us on the Surgical Oncology Clinics Podcast as we delve into the January 2024 issue focusing on "Hepatocellular Carcinoma." Guest Editors Dr. Adam C. Yopp and Maria B. Majella Doyle, along with Consulting Editor Timothy M. Pawlik, dissect the article topics to provide valuable insights into the latest advancements in hepatocellular carcinoma. Access the articles discussed in this episode at https://bit.ly/SOCJan2024 and stay updated by following us on Twitter: @SurgicalClinics. Tune in to gain expert perspectives and stay informed on the evolving landscape of surgical oncology in the context of hepatocellular carcinoma.

This week we delve into the world of adult congenital heart disease to review the topic of liver disease in the Fontan patient and specifically, hepatocellular carcinoma (HCC). What is the prevalence of this disease in the Fontan single ventricle adult patient? How effective are scores like the MELD-XI or Fibrosis-4 Index at identification of HCC in the Fontan patient? How should the Fontan adult patient be surveilled for this form of cancer? What evidence is there that earlier identification of HCC is associated with better outcomes? What may prove to be the most important factor in protection of the liver in the Fontan patient? Dr. Yuli Kim, Director of the ACHD program at The University of Pennsylvania shares her deep insights this week into this important topic. DOI: 10.1093/eurheartj/ehad788

Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data.   Topics also include:  • Efficacy and safety of IO and IO combinations in HCC • How to select between the two 1st-line IO-based treatment options based on clinical factors • Future treatment in unresectable HCC   Clinical Takeaways • Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape • Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies • Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up • IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary • In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits   Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

"'If we know activity, or sphere activity, at the time of delivery, and we know the dose to tumor, and we know the dose that we gave, we could figure out where the sphere concentrations are ... but we'd need to figure out what the dose to tumor is.' And he was like, 'Just do it in Simplicit90Y.' And at that point it was basically like, 'Oh, boom—just use the dosimetry tool we have to solve a problem. And so, that's where we are."—Tyler Sandow, MD In this Journal of Vascular and Interventional Radiology (JVIR) audio episode, lead author Tyler Sandow, MD, speaks with journal Managing Editor Ana Lewis about his November 2024 paper, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres."Related resources:Read the original article, "Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres," by Tyler Sandow, MD, Juan Gimenez, MD, Kelley Nunez, PhD, Richard Tramel, MD, Patrick Gilbert, MD, Brianna Oliver, MD, Michael Cline, MD, Kirk Fowers, PhD, Ari Cohen, MD, and Paul Thevenot, PhDRead the related commentary, "Known Unknowns: Gaps in Dose Distribution in Radioembolization, and in Our Understanding of Them," by A. Kyle Jones, MDRead the authors' response, "The Sphere Conundrum: Author's Reply to Commentary on Voxel-Based Dosimetry with Glass Microspheres," by Tyler Sandow, MD, Juan Gimenez, MD, Kirk Fowers, PhD, and Paul Thevenot, PhDSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

This recording features audio versions of October 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Outcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry ReadOpen access: Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres ReadClinical Effectiveness of Drug-Eluting Microsphere Transcatheter Arterial Chemoembolization Combined with First-Line Chemotherapy as the Initial Treatment for Patients with Unresectable Intrahepatic Cholangiocarcinoma ReadComparison of Small-Sized (70–150 μm) and Intermediate-Sized (100–300 μm) Drug-Eluting Embolics for Transarterial Chemoembolization of Small Hepatocellular Carcinomas (≤3 cm) ReadOpen access: Technical Feasibility and Outcome of Cryoablation of Aneurysmal Bone Cysts in Pediatric Patients ReadPrimary Limb-Based Patency for Chronic Limb-Threatening Ischemia Treated with Endovascular Therapy Based on the Global Limb Anatomic Staging System ReadOpen access: Initial Outcomes of Embolization for Type II Endoleak: Comparison of n-Butyl Cyanoacrylate–Ethiodized Oil Mixture with n-Butyl Cyanoacrylate– Ethiodized Oil–Ethanol Mixture ReadTrack Sealing in CT-Guided Lung Biopsy Using Gelatin Sponge Slurry versus Saline in Reducing Postbiopsy Pneumothorax: A Prospective Randomized Study ReadJVIR and SIR thank all those who helped record this episode:Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineAbstract readers:Maximillion Hayama, Duke University School of MedicineLana Kamel, University of Minnesota Medical SchoolJessalyn Yam, University of Illinois College of Medicine at ChicagoSiddak Dhaliwal, University of Missouri School of MedicineJason Hoang, The Ohio State University College of MedicineAkumbir Singh Grewal, St. George University School of MedicineMillennie Chen, University of California Riverside School of MedicineDaniel Roh, Loma Linda University School of Medicine Support the showSupport the show

In the face of the rising incidence of liver disease, how is your multidisciplinary team using imaging for surveillance and management of patients with hepatocellular carcinoma (HCC)? Credit available for this activity expires: 9/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001653?ecd=bdc_podcast_libsyn_mscpedu

This recording features audio versions of October 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Mortality, Safety, and Effectiveness of Paclitaxel-Containing Balloons and Stents in the Femoropopliteal Artery: Systematic Review and Meta-Analysis of Randomized Controlled Trials since 2018 ReadEffect of Filtered Blood Return on Outcomes of Pulmonary Aspiration Thrombectomy ReadThe Predictive Value of Qanadli and Miller Index Scores in Patients with Intermediate-High–Risk and High-Risk Pulmonary Emboli Undergoing Aspiration Thrombectomy ReadImageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial ReadMagnetic Resonance Imaging–Guided Cryoablation of Prostate Cancer Lymph Node Metastasis ReadCorrelation of Ablation Volume with Renal Function Loss after Cryoablation in Solitary Functioning Kidneys ReadIntra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model ReadJVIR and SIR thank all those who helped record this episode:Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Sonya Choe, University of California Riverside School of MedicineAbstract readers:Melissa Millett, MD, Southeast HealthSonya Choe, University of California Riverside School of MedicineAlena Khalil, Nova Southeastern University Dr. Kiran Patel College of Osteopathic MedicineAndrew Brandser, Frank H. Netter MD School of MedicineMark Oliinik, Loma Linda University School of MedicineDaniel Roh, Loma Linda University School of MedicineMillennie Chen, University of California Riverside School of MedicineSupport the showSupport the show

In this episode, George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU), and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including: Consequences to poor adherence to antiviral therapyStrategies to promote medication adherence (eg, patient education, setting up routines)The role of routine monitoring to prevent complications related to HBV such as hepatocellular carcinoma  Presenter: George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU)Specialist in Gastroenterology & HepatologyChairman and Senior Consultant in Gastroenterology and HepatologyHumanity and Health Medical GroupHong Kong, ChinaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/49TuZ8UGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Dr. Lauren Kim discusses efficacy and safety of Y-90 radiation segmentectomy for hepatocellular carcinoma with Dr. Ammar Sarwar.  Efficacy and Safety of Radiation Segmentectomy with 90Y Resin Microspheres for Hepatocellular Carcinoma. Sarwar et al. Radiology 2024; 311(2):e231386.  

Bardia Nadim, MD discusses a recently published article on the short-term out-of-pocket and total costs of care after ablation, resection, or transplant for early-stage hepatocellular carcinoma, using national SEER-Medicare data. The analysis reveals significant cost differences among these treatments, with ablation being notably less expensive. Dr. Nadeem is joined by Borna E. Dabiri, MD, PhD, who provides insights into the clinical implications, referral processes, post-procedural care, and future research directions.  ARTICLE TITLE - Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison

Responsible for 1.3 million deaths and 2.2 million new infections per year, viral hepatitis is the second leading cause of morbidity and mortality amongst all infectious diseases, just behind tuberculosis.  Hosts Angela Huttner and Oana Sandulescu welcome special guest and leading hepatitis expert, Professor Mojca Matičič, MD, PhD (Ljubljana, Slovenia), to refresh your knowledge on the pathogenesis of hepatitis B & C infections, review the latest direct-acting antiviral (DAA) therapies, map out some countries' successful elimination initiatives, and understand challenges remaining for others. In recognition of World Hepatitis Day this Sunday, 28 July, a day dedicated to raising awareness about viral hepatitis, we are releasing our latest episode a few days early. The World Hepatitis Day theme this year is: it's time for action! The Communicable team urges our listeners to inform themselves and others, and to test, treat, and vaccinate against viral hepatitis.  This episode was peer reviewed by Dr. Liem Luong of CIC Cochin Pasteur, Hôpital Cochin-Port Royal, Assistance Publique-Hôpitaux de Paris, Paris, France. LiteratureWorld Hepatitis Day 2024: It's time for action. Geneva: World Health Organization; 2024. https://www.who.int/campaigns/world-hepatitis-day/2024 Method for global reporting on disease burden and service coverage data for viral hepatitis B and C, 2022. In: Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. doi: 10.2471/B09024. The European Association of the Study of the Liver (EASL). EASL Congress Milan, Italy 5-8 June 2024. https://www.easlcongress.eu/European Centre for Disease Prevention and Control (ECDC). ECDC Evidence brief: Prevention of hepatitis B and C in the EU/EEA. Stockholm: ECDC; 2024.  European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2024.  Burnet Institute and Kirby Institute. Australia's progress towards hepatitis C elimination: annual report 2022. Melbourne: Burnet Institute; 2022. Maticic M, Pirnat Z, Leicht A, et al. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. Harm Reduct J. 2020 Nov 19;17(1):89. doi: 10.1186/s12954-020-00439-3.

Host: Jody Takemoto, PhD Guest: Robert Wong, MD Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That's why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians diagnose and treat patients with hepatocellular carcinoma. To learn more about this tool, Dr. Jody Takemoto speaks with Dr. Robert Wong. Not only is he a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine, but he also helped develop the tool.

Host: Jody Takemoto, PhD Guest: Robert Wong, MD Hepatitis B is one of the leading causes of liver cancer globally, underscoring the importance of screening, diagnosing, and treating patients appropriately. However, there are several considerations to keep in mind when caring for patients with hepatocellular carcinoma with hepatitis B co-infection, which is why Dr. Jody Takemoto speaks with Dr. Robert Wong about those factors and essential management strategies. Dr. Wong is a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Hashem El-Serag from the Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA, on the paper "Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis" published in paper copy in Gut in June 2024. Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p). 

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib (tyrosine kinase inhibitor). Will immunotherapy take the reigns as the preferred agents? Our second study is Compassion-08, (Michael has an abundance of this). The trial is unique as it involves a first-in-class bispecific antibody targeting PD-1 and CTLA-4 (cadonilimab in combination with lenvatinib).Interesting times ahead in the HCC space Hosted on Acast. See acast.com/privacy for more information.

Hepatocellular carcinoma is the most common primary liver cancer. It is a complex disease that requires a multidisciplinary team — for patients, that can mean a drawn-out array of appointments. Robert Cannon, M.D., surgical director of the UAB Liver Transplant Program, discusses the new Hepatocellular Carcinoma Clinic (HCC), which brings together relevant specialists for the benefit of patients. As he explains, patients can now leave one appointment with a diagnosis and a care plan built by the entire team. Learn more about exciting clinic trails offered through the HCC.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

This recording features audio versions of May 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Prediction of Mortality and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Placement: Baseline and Longitudinal Body Composition Measurement ReadThree-Year Outcomes of the Abre Venous Self-Expanding Stent System in Patients with Symptomatic Iliofemoral Venous Outflow Obstruction ReadInjection of n-Butyl-2-Cyanoacrylate into the Abdominal Aortic Aneurysm Sac during Endovascular Aortic Repair to Prevent Type II Endoleaks Caused by Lumbar Arteries ReadTumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma ReadRadioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma ReadFever at Time of Leukemia Diagnosis in Children: Predictor of Bloodstream Infection or Catheter Removal?  ReadJVIR and SIR thank all those who helped record this episode:Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Sonya Choe, University of California Riverside School of MedicineAbstract readers:Isabelle Barbosa, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutJustin Cook, University of Central Florida College of MedicineJohn Ficke, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAnna Hu, George Washington University School of Medicine and Health Sciences, Washington, D.C.Eric Chang, University of Illinois College of Medicine, ChicagoErin Moore, Northeast Ohio Medical University©  Society of Interventional RadiologySupport the show

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, in this engaging podcast episode as they delve into the treatment landscape for hepatocellular carcinoma (HCC) with Dr. Tanios S. Bekaii-saab from Mayo Clinic. The discussion covers the treatment options for different stages of HCC, including liver transplant, local therapy, and systemic treatments. Dr. Tanios S. Bekaii-saab provides insights on utilizing Atezolizumab with Bevacizumab, dual checkpoint inhibitors, and TKIs in advanced or metastatic HCC. Clinical pearls on managing side effects and patient selection criteria are also discussed. Don't miss this comprehensive overview of HCC treatment strategies in both community and academic settings. Stay informed and educated on the latest developments in oncology with the Oncology Brothers podcast series. Subscribe now for more insightful discussions on various cancer types and treatment approaches. #Oncology #HepatocellularCarcinoma #CancerTreatment #PodcastEpisode

Dr. Linda Chu discusses a meta-analysis of LR-5 in LI-RADS 2018 vs. Revised LI-RADS for diagnosis of hepatocellular carcinoma with Dr. Mustafa Bashir.  Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis. Goins et al. Radiology 2023; 309(3):e231656.

This recording features audio versions of April 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Genicular Artery Embolization: A Review of Essential Anatomic Considerations ReadLocoregional Therapies for Hepatocellular Carcinoma prior to Liver Transplant: Comparative Pathologic Necrosis, Radiologic Response, and Recurrence ReadFeasibility Study of Transarterial Chemotherapy Followed by Chemoembolization for Recurrent Breast Cancer ReadSafety and Technical Feasibility of Percutaneous Renal Cryoablation of Central Tumors without Pyeloperfusion ReadTransarterial Embolization for Adhesive Capsulitis of the Shoulder: Midterm Outcomes on Function and Pain Relief ReadEffectiveness and Safety of Large-Bore Aspiration Thrombectomy for Intermediate or High-Risk Pulmonary Embolism ReadPercutaneous Management of Dialysis Access Steal Syndrome: Interventions and Outcomes from a Single Institution's 20-Year Experience ReadJVIR and SIR thank all those who helped record this episode:Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineAbstract readers:Dhanush Reddy, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MassachusettsAshwin Mahendra, Florida Atlantic University, Charles E. Schmidt College of MedicineAlena Khalil, MA, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic MedicineHannah Curtis, Loma Linda University School of MedicineMelissa Millett, St. George's UniversityMaximillian Denys, University of California Riverside School of MedicineJacob Knittel, Creighton University School of Medicine Phoenix Regional Campus©  Society of Interventional RadiologySupport the show

Dr Robin K (Katie) Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Mark Yarchoan from the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, Maryland, discuss clinical decision-making with numerous treatment strategies for hepatocellular carcinoma and biliary tract cancers. CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary2).

Dr. John Gordan discusses the newest evidence-based guideline update from ASCO on systemic therapy for advanced hepatocellular carcinoma (HCC). He shares the updated recommendations for first-, second-, and third-line therapy for patients with Child-Pugh Class A liver disease, guidance for patients with Child-Pugh Class B liver disease. Dr. Gordan also touches on the importance of this guideline for both clinicians and patients and the outstanding questions regarding treatment options for HCC. Read the full guideline, “Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update” at www.asco.org/gastrointestinal-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.02745   Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today I'm interviewing Dr. John Gordon from the University of California, San Francisco, lead author on "Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update." Thank you for being here, Dr. Gordon. Dr. John Gordon: Of course, happy to be here. Brittany Harvey: Before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Gordon, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes.   So, to jump into the content of this episode, first, Dr. Gordon, what prompted this update to the Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline, which was last published in 2020?  Dr. John Gordon: So, both the initial guideline in 2020 and then the update now were driven by advances in the standard of care. The original 2020 guideline was actually held for a little bit so that we could incorporate the availability of atezolizumab plus bevacizumab, which just reported back and then received FDA approval during 2020. We were happy to be able to provide what was a very timely update to clinicians about being able to use that new regimen that had really changed the face of therapeutics for advanced HCC. The update was driven again by a shift in therapeutics, specifically it was the presence of much more evidence for the use of combination CTLA-4, PD-1 or PD-L1 immunotherapy strategies. The primary thing was the availability of durvalumab plus tremelimumab, which was studied in the so-called HIMALAYA phase III trial. The key shift in this guideline was being able to incorporate those data as a second first-line option. Furthermore, when the 2020 guideline was released, data were just becoming available about the combination of ipilimumab and nivolumab, and were not covered in any great detail. So we wanted to be able to be sure to incorporate both of those regimens, which we thought were quite significant in the current therapy for advanced HCC. Brittany Harvey: Appreciate you providing that background on the evidence informing both the original guideline and this update. Next, I'd like to review the key recommendations of this update. So, starting with, what is recommended for first-line therapy? Dr. John Gordon: The current recommendation in the first-line setting is to offer patients either atezolizumab plus bevacizumab, sometimes called atezo-bev or durvalumab plus tremelimumab. But, at this time, those two regimens we're not able to distinguish between them based on the primary evidence available. But there are a few distinctions in the studies and the patients that physicians may wish to consider. In particular, because atezo plus bev contains an immune therapy and then an anti vascular agent, for patients who are not eligible for antivascular agents or for whom an antivascular therapy might be of higher risk, for example, people with a history of esophageal varices or people with peripheral arterial disease, we would encourage physicians to preferentially consider durva plus treme.  Similarly, for patients where reactivation of an autoimmune disorder is a particular concern, staying away from the more potent immune combination is also advised. But again, the data themselves support the consideration of both, and it's really up to the provider, their multidisciplinary team, and then communication with the patient to determine what is optimal for that patient.   In addition, in the frontline setting, it is advised that for those patients who are unable to receive atezo plus bev or durva plus treme, sorafenib and lenvatinib, the traditional tyrosine kinase inhibitors that were more commonly used prior to 2020, may also be considered in the frontline setting. Furthermore, for some patients, it's also reasonable to consider the use of durvalumab alone, which is the PD-L1 inhibitor component of the durva-treme combination.  Brittany Harvey: Understood. It's helpful to understand which regimens are optimal for which patient population and options that are available for shared decision making between patients and their clinicians.  So then, following those recommendations for first-line treatment, what is recommended for second-line therapy? Dr. John Gordon: One of the things I want to be clear about the second-line recommendations is that these are largely driven by expert opinion rather than primary research studying the use of these agents after either atezo plus bev or durva plus treme. So, if you look at the history of HCC drug development, five or ten years ago, when we were confined to the use of sorafenib in the frontline setting, many studies explicitly studied the second and later-line population. But in the current era, where new frontline therapies have supplanted those agents, it becomes a little bit harder to provide a truly evidence-based answer. As a result, the recommendation is, frankly, to consider all of the options of FDA-approved agents and just as was the case of the frontline setting, to balance what might be patient-specific characteristics, both in terms of comorbidities and also ability to adhere with these regimens, which are not the easiest. All of those things should be considered when opting for a second-line agent.  Just to be slightly more explicit about it, for those patients who've received frontline atezo-bev, the considerations would be either transitioning to a tyrosine kinase inhibitor, most classically sorafenib, lenvatinib, or cabozantinib, or in principle, ramucirumab, the biologic antivascular agent, or a CTLA-4 and PD-1 or PD-L1 combination, such as durva-treme or nivolumab plus ipilimumab. Conversely, for those patients who might have received durva-treme in the frontline setting, it's reasonable to consider either a TKI or atezo plus bev. Brittany Harvey: Absolutely. Thank you for reviewing both those recommendations and the level of evidence behind those. I think it's important that even in areas where the expert panel didn't have a lot of evidence to go off of, there are still recommendations available for clinicians that are based on expert opinion.  So then, following those second-line therapy options that you just described, what recommendations did the expert panel make for third-line therapy? Dr. John Gordon: So, regarding the recommendation for third-line therapy, one of the things that we did want to make clear as a panel is that third-line therapy is a reasonable consideration in a subset of HCC patients. Quite often, five or ten years ago, it was very seldom that a patient might be considered for frontline therapy because of the burden of toxicity and/or disease progression during the first two lines. But now, for patients with intact liver function and good performance status, I think it's very reasonable to consider the same list of agents that might have been considered for second line. And again, I think the general guidance here is if you've already given your patient both atezo-bev and some kind of CTLA-4 and PD-1 combination, it's probably best to use a non-overlapping regimen, something like a TKI. If, in the frontline setting, you followed atezo-bev by TKI or durva-treme by TKI, then it would be reasonable to look at the immune therapy combination that the patient hadn't received yet. Unfortunately, again, at this point, this is all at the level of expert guidance and personal experience. But just thinking about the mechanistic rationale behind these different combinations, and which ones your patient has had the opportunity to benefit from yet, is probably the best guidance that we can give as you move into the later line. Brittany Harvey: Definitely. Thank you for reviewing that guidance as well.  So then, these recommendations that you've already described refer to patients with Child-Pugh Class A liver disease. What is recommended in the guideline for patients with Child-Pugh Class B advanced hepatocellular carcinoma? Dr. John Gordon: Thanks. I think that's another important question, and it's a part of the field that's still evolving. So this is in some ways similar to the situation for third line therapy. The level one evidence that we have and the clinical trials that were done were almost exclusively done in the context of Child-Pugh A liver function. But we know well that many patients with hepatocellular carcinoma have some degree of impairment to their liver function, making them Child-Pugh Class B or beyond. Similar to third line therapy, we do believe that it's appropriate to cautiously consider systemic therapy for these patients, particularly a better compensated patient with Child-Pugh Class B liver function may be considered. The same systemic therapy options that are considered for patients with Child-Pugh Class A may be considered here, even to the level of considering atezo-bev or durva plus treme. I will also acknowledge, though, that when considering the liver function, bleeding risk, portal hypertension, and all of the other issues that may be at play, it may end up being safer for clinicians to consider monotherapy with an agent like durvalumab or using a TKI, by simple virtue of the fact that if complications ensue, treatment can be interrupted and the therapeutic will leave the patient's system relatively promptly. The key take home here is please do consider systemic therapy in this population, but also consider it with caution, with an understanding that the underlying hepatic dysfunction also plays a role in considering and affecting the outcome. Brittany Harvey: Thank you for reviewing those recommendations for patients with Child-Pugh Class B advanced HCC and all of these recommendations, which are based off of expert review of the evidence and consensus of the entire expert panel.  So then, Dr. Gordon, in your view, what is the importance of this guideline update, and how will it impact both clinicians and patients with hepatocellular carcinoma? Dr. John Gordon: I think the impact of this guideline update was really to open the field and really just make clear that the use of CTLA 4-containing combinations was appropriate for patients with HCC because those data were not available at the time of the last guideline and to try to provide some insight about where and when to incorporate them. We really think that these agents have the potential to significantly impact outcomes for patients with HCC, and so we wanted to be clear that these can be considered therapeutically even after frontline use of a PD-L1 inhibitor like atezolizumab. And so I think the key objective of this guideline is really to be enabling and really to make it clear that within the now somewhat surprisingly broad range of approved agents that we have for HCC, these options are on the table and may be used in succession, depending on patient-specific tolerance and their clinical course.  Brittany Harvey: Absolutely. So then you've specifically mentioned that both the original guideline and the guideline update were developed to provide timely guidance from recently published randomized clinical trials. So what are the outstanding questions still regarding treatment options for advanced hepatocellular carcinoma?  Dr. John Gordon: I think those questions are really reflected in one of the things which is challenging about these guidelines, which is that it's a very kind of open set of guidelines. We provide clinicians with a range of options, but we're really not in a position to provide much evidence-based guidance around treatment selection beyond the sort of careful avoidance of contraindications. I think that there will continue to be drug development for HCC. I think there are more potent immune therapies that are currently in use for other tumors that are being studied here, and I think we do hope to see new agents in future guidelines as well. But I really feel like the key question is going to be starting to stratify patients for who's going to be most likely to benefit from exposure to an antivascular agent, who's going to be more likely to benefit from exposure to a more potent immunotherapy so that we can give our patients the best medicine for them in the first setting, and that we're less in the position of having to sample the available options to see which one might work for our patient. And I think that's going to require significant effort, particularly, honestly, in academic medicine, as these medicines start to get used, to develop the kinds of data that will enable identification of biomarkers and mechanisms of response, as well as identification of efficacy, which has been this sort of key limiting step in HCC therapeutics for the last 10 years. Now that we've got so many effective agents, we would like to see them be more effective, but nevertheless, it's been huge strides forward. Then the question is, who gets what when?  I think the other place of interesting development right now is the integration of locoregional therapies like embolization procedures, either chemoembolization or radioembolization, as well as stereotactic body radiotherapy with systemic therapy. My suspicion is that it's going to take a little bit more time before the use of these is really well understood and how they might fit into the current standards of care. But we're starting to see some large studies tackling this question. I think that we will see impact of the combinations of systemic therapy and local regional therapy in guidelines to come in parallel to a better understanding of which treatment is right for which patient. Brittany Harvey: We'll look forward to all of the future developments in the care of patients with advanced hepatocellular carcinoma, and look forward to inclusion of all of the things that you just mentioned into guidelines in the future.  So I want to thank you, Dr. Gordon, for all of your work that you've done to update these guidelines and for taking the time to speak with me today.  Dr. John Gordon: Absolutely. And I actually just want to express what a great experience I've had working with the ASCO Guidelines team. I think that this is very challenging work, and I really appreciate the professionalism and commitment that they bring to it. I think it has a huge impact, and I'm glad to be part of it. Brittany Harvey: Absolutely. And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and inform. It is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

References Cell Death Dis. 2020 Dec; 11(12): 1065. Genome Res. 2000 Oct; 10(10): 1445–1452. https://www.genecards.org/cgi-bin/carddisp.pl?gene=NIPBL Genes Dis. 2022 Jan; 9(1): 116–127 Schubert, F. 1824. Quartet 14 in D minor, D 810, "Death and the Maiden" https://youtu.be/XF_6vSlmm4w?si=CGTn3R6Tkn6LsMLv Browne,J. 1993. "Sky Blue and Black". https://youtu.be/Ty1I6dtC2zc?si=QHuwDiQUDh-4S5VP --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Dr Ahmed Omar Kaseb from the University of Texas MD Anderson Cancer Center in Houston, Texas, and Prof Arndt Vogel from Schwartz Reisman Liver Research Centre in Toronto, Ontario, discuss the optimal selection and sequencing of checkpoint inhibitor therapy for patients with hepatobiliary cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASCOGI24/Hepatobiliary1).

This recording features audio versions of February 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Radiation Major Hepatectomy Using Ablative Dose Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma 5 cm or Larger ReadYttrium-90 Transarterial Radioembolization of Primary Lung Cancer Metastases to the Liver ReadPercutaneous Cryoablation of Recurrent or Oligometastatic Tumors in Thoracoabdominal Soft Tissues: Safety, Effectiveness, and Technical Aspects ReadTargeted versus Empiric Embolization for Delayed Postpancreatectomy Hemorrhage: A Retrospective Study of 312 Patients ReadEarly Outcomes of Interwoven Nitinol Wire Stent Placement versus Endarterectomy for the Treatment of Atherosclerotic Disease of the Common Femoral Artery ReadPercutaneous Deep Venous Arterialization in Patients with No-Option Critical Limb Ischemia Performed in an Office-Based Laboratory Setting ReadGeospatial and Socioeconomic Disparities in Access to IR Care in the United States ReadJVIR and SIR thank all those who helped record this episode:Host and audio editor:Manbir Singh Sandhu, University of California Riverside School of MedicineAbstract readers:Hannah Curtis, Loma Linda University School of Medicine, CaliforniaTaji Kommineni, MD, JD, LLM, American University of Antigua College of MedicineAlena Khalil, MA, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, FloridaSai Dhanush Reddy Jeggari, MD, Massachusetts General HospitalAshwin Mahendra, Florida Atlantic University, Charles E. Schmidt College of MedicineJeremy Brown, DO, MS, Kaweah Health Medical Center, CaliforniaIsabelle Barbosa, Frank H. Netter MD School of Medicine at Quinnipiac University, Connecticut©  Society of Interventional RadiologySupport the show

Full article: https://www.ajronline.org/doi/10.2214/AJR.23.30156  Sid Dogra, MD discusses an article in which the authors investigate various combinations of imaging acquisitions and diagnostic criteria for hepatocellular carcinoma using contrast-enhanced ultrasound with the agent perfluorobutane.

This recording features audio versions of December 2023 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Sclerotherapy of Venous Malformations Using Polidocanol: Effectiveness, Safety, and Predictors of Outcomes and Adverse Events ReadComparison of the Safety of Transjugular and Percutaneous Liver Biopsies ReadEffect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry ReadHepatic Hypertrophy in Normal and Cirrhotic Livers Following Portal Vein Embolization: Comparative Assessment of 2 Different Embolic Regimens in a Large Animal Model ReadGenicular Artery Embolization for Treatment of Knee Osteoarthritis: Interim Analysis of a Prospective Pilot Trial Including Effect on Serum Osteoarthritis-Associated Biomarkers ReadQuantifying Change in Perfusion after Genicular Artery Embolization with Parametric Analysis of Intraprocedural Digital Subtraction Angiograms Read JVIR and SIR thank all those who helped record this episode:Host:Rommell Noche, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAudio editor:Manbir Sandhu, University of California Riverside School of MedicineAbstract readers:Melissa Millett, St. George's University, GrenadaAlena Khalil, MA, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, FloridaChristopher Loiselle, MS, Lincoln Memorial University-DeBusk College of Osteopathic Medicine, TennesseeJonathan Dzielski, Kansas City University, MissouriAndrew Brandser, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutTaji Kommineni, MD, JD, LLM, American University of Antigua©  Society of Interventional RadiologySupport the show

References Front Immunol. 2018; 9: 476 Nature Reviews Gastroenterology & Hepatology 2023. 20: 662–678 (2023) Cells. 2021 Jun; 10(6): 1332. Traffic, (Traditional. arr. S Winwood )1970. "John Barleycorn Must Die" https://youtu.be/icyPFsIcAV0?si=XSVxsiojZBrwGPx6 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Featuring perspectives from Dr Ghassan Abou-Alfa and Dr Daneng Li, including the following topics: Introduction: Etiology of Hepatocellular Carcinoma (HCC) and IO Response (0:00) First-Line Therapy for Advanced HCC — Dr Abou-Alfa (17:42) Second- and Later-Line Therapy for Advanced HCC; Emerging Considerations for Patients with Resectable HCC — Dr Li (38:12) CME information and select publications